MX337650B - Metodos para predecir el desenlace clinico del cancer. - Google Patents

Metodos para predecir el desenlace clinico del cancer.

Info

Publication number
MX337650B
MX337650B MX2012005822A MX2012005822A MX337650B MX 337650 B MX337650 B MX 337650B MX 2012005822 A MX2012005822 A MX 2012005822A MX 2012005822 A MX2012005822 A MX 2012005822A MX 337650 B MX337650 B MX 337650B
Authority
MX
Mexico
Prior art keywords
cancer
methods
genes
clinical outcome
prognosis
Prior art date
Application number
MX2012005822A
Other languages
English (en)
Other versions
MX2012005822A (es
Inventor
Joffre B Baker
Maureen T Cronin
Francois Collin
mei-lan Liu
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of MX2012005822A publication Critical patent/MX2012005822A/es
Publication of MX337650B publication Critical patent/MX337650B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a métodos para determinar el pronóstico y el tratamiento adecuado para pacientes con diagnóstico de cáncer, basándose en los niveles de expresión de uno más biomarcadores. De manera más particular, la invención se refiere a la identificación de genes, o de conjuntos de genes, capaces de distinguir a los pacientes de cáncer de mama con buen pronóstico clínico respecto de aquellos que tienen un mal pronóstico clínico. La invención también proporciona métodos para obtener un informe genómico personalizado para un paciente de cáncer. La invención también se refiera a sistemas de computadora y software para análisis de datos utilizando los métodos de pronóstico y estadística divulgados en la presente.
MX2012005822A 2009-11-23 2010-11-19 Metodos para predecir el desenlace clinico del cancer. MX337650B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26376309P 2009-11-23 2009-11-23
PCT/US2010/057490 WO2011063274A2 (en) 2009-11-23 2010-11-19 Methods to predict clinical outcome of cancer

Publications (2)

Publication Number Publication Date
MX2012005822A MX2012005822A (es) 2012-06-19
MX337650B true MX337650B (es) 2016-03-14

Family

ID=44060376

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012005822A MX337650B (es) 2009-11-23 2010-11-19 Metodos para predecir el desenlace clinico del cancer.
MX2016003089A MX363817B (es) 2009-11-23 2010-11-19 Métodos para predecir el desenlace clínico del cáncer.
MX2019003811A MX2019003811A (es) 2009-11-23 2012-05-18 Metodos para predecir el desenlace clinico del cancer.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2016003089A MX363817B (es) 2009-11-23 2010-11-19 Métodos para predecir el desenlace clínico del cáncer.
MX2019003811A MX2019003811A (es) 2009-11-23 2012-05-18 Metodos para predecir el desenlace clinico del cancer.

Country Status (13)

Country Link
US (4) US20110123990A1 (es)
EP (4) EP4350001A3 (es)
JP (7) JP5964752B2 (es)
AU (1) AU2010321829B2 (es)
CA (2) CA3043089A1 (es)
DK (1) DK2504451T3 (es)
ES (1) ES2735993T3 (es)
HU (1) HUE044374T2 (es)
IL (5) IL219051A (es)
MX (3) MX337650B (es)
NZ (1) NZ599194A (es)
PL (1) PL2504451T3 (es)
WO (1) WO2011063274A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP2163650B1 (en) 2004-04-09 2015-08-05 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
ES2778851T3 (es) * 2004-11-05 2020-08-12 Genomic Health Inc Predicción de la respuesta a la quimioterapia mediante el uso de marcadores de expresión génica
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
CN102132160A (zh) * 2008-06-26 2011-07-20 达纳-法伯癌症研究院有限公司 与转移有关的信号和决定子以及它们的使用方法及用途
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
HUE044374T2 (hu) * 2009-11-23 2019-10-28 Genomic Health Inc Módszerek rák klinikai kimenetelének elõrejelzésére
US9551034B2 (en) 2010-01-11 2017-01-24 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
JP2013532482A (ja) 2010-07-27 2013-08-19 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現を用いた前立腺癌の予後を定量化する方法
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
JP2014509868A (ja) * 2011-03-26 2014-04-24 オレゴン ヘルス アンド サイエンス ユニバーシティー 癌の予後のための遺伝子発現予測因子
AU2012203810B2 (en) * 2011-06-22 2013-12-05 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
WO2013006495A2 (en) * 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
AU2012281152B2 (en) * 2011-07-13 2017-09-07 The Multiple Myeloma Research Foundation, Inc. Methods for data collection and distribution
AU2012296405B2 (en) * 2011-08-16 2016-03-17 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of breast cancer
JP6147755B2 (ja) * 2011-11-08 2017-06-14 ジェノミック ヘルス， インコーポレイテッド 乳癌の予後を予測する方法
JP5805518B2 (ja) * 2011-12-21 2015-11-04 株式会社島津製作所 マルチプレックス大腸がんマーカーパネル
NZ722902A (en) 2012-01-31 2017-12-22 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer
GB201206323D0 (en) * 2012-04-10 2012-05-23 Immunovia Ab Methods and arrays for use in the same
EP2839034A4 (en) * 2012-04-20 2016-01-06 Sloan Kettering Inst Cancer GENE EXPRESSION PROFILES ASSOCIATED WITH METASTASIC BREAST CANCER
US20150299799A1 (en) * 2012-10-05 2015-10-22 Michael Sturzl Method for Detecting an Increased Risk or Incidence of Colorectal Cancer
EP2920322B1 (en) 2012-11-16 2023-01-11 Myriad Genetics, Inc. Gene signatures for cancer prognosis
KR101672531B1 (ko) * 2013-04-18 2016-11-17 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도
SG11201506987VA (en) * 2013-05-30 2015-10-29 Genomic Health Inc Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
WO2014195032A1 (en) * 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
US20170073763A1 (en) * 2014-03-12 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Methods and Compositions for Assessing Patients with Non-small Cell Lung Cancer
WO2015175692A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2016046640A2 (en) 2014-09-26 2016-03-31 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
WO2016092299A1 (en) * 2014-12-09 2016-06-16 Medical Research Council Methods and kits for predicting the response to therapy of cancer
US10704081B2 (en) 2015-10-30 2020-07-07 Exact Sciences Development Company, Llc Multiplex amplification detection assay
EP3389481A4 (en) 2015-12-18 2019-05-22 Clear Gene, Inc. PROCESSES, COMPOSITIONS, KITS AND DEVICES FOR FAST LANALYSIS OF BIOLOGICAL MARKERS
WO2018048354A1 (en) * 2016-09-07 2018-03-15 Agency For Science, Technology And Research A method of identifying risk of cancer and therapeutic options
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
WO2018212192A1 (ja) * 2017-05-18 2018-11-22 京都府公立大学法人 癌の予後及び／又は転移可能性を評価する方法及びマーカー
EP3513280A4 (en) 2017-11-13 2020-07-22 The Multiple Myeloma Research Foundation, Inc. INTEGRATED, MOLECULAR, OMIC, IMMUNOTHERAPY, METABOLIC, EPIGENETIC AND CLINICAL DATABASE
WO2019173644A1 (en) * 2018-03-08 2019-09-12 University Of Notre Dame Du Lac Systems and methods for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon
JP7199045B2 (ja) * 2018-04-13 2023-01-05 国立大学法人大阪大学 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム
JP7444376B2 (ja) 2018-09-21 2024-03-06 国立大学法人 東京大学 がんの予後判定方法
JP2019032334A (ja) * 2018-10-03 2019-02-28 イムノヴィア・アクチエボラーグ 乳癌関連の疾患状態を決定する方法およびこの方法における使用のためのアレイ
KR102216645B1 (ko) * 2018-10-29 2021-02-17 사회복지법인 삼성생명공익재단 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도
JP2022512152A (ja) * 2018-12-08 2022-02-02 ピーエフエス・ジェノミクス・インコーポレイテッド 乳がんの予後についてのトランスクリプトームプロファイリング
CN111235270B (zh) * 2019-08-29 2022-04-29 北京臻知医学科技有限责任公司 一种基于高通量测序法的肿瘤抗原表达检测引物及试剂盒
US20210358573A1 (en) * 2020-01-23 2021-11-18 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1410011B1 (en) * 2001-06-18 2011-03-23 Rosetta Inpharmatics LLC Diagnosis and prognosis of breast cancer patients
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US7705120B2 (en) * 2001-06-21 2010-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP2261368A1 (en) * 2002-03-13 2010-12-15 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040067234A1 (en) * 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
JP4906505B2 (ja) * 2003-07-10 2012-03-28 ジェノミック ヘルス， インコーポレイテッド 癌診断のための発現プロフィールアルゴリズムおよび試験
WO2005086891A2 (en) * 2004-03-05 2005-09-22 Rosetta Inpharmatics Llc Classification of breast cancer patients using a combination of clinical criteria and informative genesets
US20080299550A1 (en) * 2004-09-20 2008-12-04 Bayer Healthcare Ag Methods and Kits For the Prediction of Therapeutic Success and Recurrence Free Survival In Cancer Therapy
CA2612021A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
TWI304443B (en) * 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
WO2007123772A2 (en) * 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
JP2010524456A (ja) * 2007-04-16 2010-07-22 イプソゲン 乳癌に罹患している雌哺乳動物に対する臨床転帰の傾向を評価する方法
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
WO2009095319A1 (en) * 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
WO2009132928A2 (en) * 2008-05-02 2009-11-05 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis
HUE044374T2 (hu) * 2009-11-23 2019-10-28 Genomic Health Inc Módszerek rák klinikai kimenetelének elõrejelzésére

Also Published As

Publication number Publication date
AU2010321829B2 (en) 2015-07-30
MX2012005822A (es) 2012-06-19
EP2504451B1 (en) 2019-06-05
US20170211154A1 (en) 2017-07-27
DK2504451T3 (da) 2019-08-05
NZ599194A (en) 2014-07-25
JP2022169647A (ja) 2022-11-09
EP2504451A4 (en) 2016-07-06
IL276487B (en) 2022-03-01
CA3043089A1 (en) 2011-05-26
CA2776751A1 (en) 2011-05-26
EP3556867A1 (en) 2019-10-23
JP2022166064A (ja) 2022-11-01
MX363817B (es) 2019-04-04
EP3739060A1 (en) 2020-11-18
US20110123990A1 (en) 2011-05-26
US20210062275A1 (en) 2021-03-04
WO2011063274A2 (en) 2011-05-26
AU2010321829A1 (en) 2012-05-03
JP2021058207A (ja) 2021-04-15
CA2776751C (en) 2019-07-02
IL219051A (en) 2016-12-29
IL264072A (en) 2019-02-28
EP4350001A2 (en) 2024-04-10
IL264072B (en) 2020-08-31
WO2011063274A3 (en) 2014-03-27
IL276487A (en) 2020-09-30
JP2018196385A (ja) 2018-12-13
HUE044374T2 (hu) 2019-10-28
IL257063B (en) 2019-01-31
EP4350001A3 (en) 2024-06-19
JP7042717B2 (ja) 2022-03-28
MX2019003811A (es) 2019-08-05
JP2013514058A (ja) 2013-04-25
JP2024037948A (ja) 2024-03-19
IL249159A0 (en) 2017-01-31
IL219051A0 (en) 2012-06-28
PL2504451T3 (pl) 2019-09-30
JP5964752B2 (ja) 2016-08-03
JP2016214245A (ja) 2016-12-22
US20190241967A1 (en) 2019-08-08
EP2504451A2 (en) 2012-10-03
ES2735993T3 (es) 2019-12-23

Similar Documents

Publication Publication Date Title
MX2019003811A (es) Metodos para predecir el desenlace clinico del cancer.
Mian et al. Role of prostate biopsy schemes in accurate prediction of Gleason scores
WO2005086891A3 (en) Classification of breast cancer patients using a combination of clinical criteria and informative genesets
MX2018011725A (es) Metodo para emplear expresion genica para determinar pronostico de cancer de prostata.
NZ593228A (en) Gene expression markers (inhba) for colorectal cancer prognosis
IL182063A0 (en) Methods and compositions for evaluating breast cancer prognosis
MX2019007814A (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
IN2012DN04944A (es)
ES2938766T3 (es) Firmas génicas para el pronóstico de cáncer
WO2004065545A3 (en) Diagnosis and prognosis of breast cancer patients
MX358656B (es) Métodos y sistemas para evaluar resultados clínicos.
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
EP2558598A4 (en) BIOMARKER BASED ON A MECHANISM ASSOCIATED WITH A MULTI-CARCINOMA INVASION
MX2016004557A (es) Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama.
Rodriguez et al. Disparities in endometrial cancer outcomes between non-Hispanic White and Hispanic women
Pavlík et al. Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000–2008
Yin et al. A 41-gene signature derived from breast cancer stem cells as a predictor of survival
WO2009082744A3 (en) Prognosis and interference-mediated treatment of breast cancer
Lund et al. Development and validation of a 5‐year mortality prediction model using regularized regression and Medicare data
Wells et al. Evolving paradigm for imaging, diagnosis, and management of DCIS
WO2006065940A3 (en) Identification and use of prognostic and predictive markers in cancer treatment
Mello et al. Machine learning supports long noncoding rnas as expression markers for endometrial carcinoma
WO2010093907A3 (en) An assay for the detection of recurrence in breast cancer using the novel tumor suppressor dear1
WO2010091296A3 (en) Emx2 in cancer diagnosis and prognosis
Zhu et al. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience

Legal Events

Date Code Title Description
FG Grant or registration